Home > Healthcare > Medical Devices > Diagnostic Devices > ivd in cardiology and neurology market
Get a free sample of IVD in Cardiology and Neurology Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of IVD in Cardiology and Neurology Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Based on product type, the market is segmented into instruments, reagents, kits, & consumables, and software & services. The reagents, kits, & consumables segment is estimated to account for USD 12 billion by 2032.
Based on technology, the IVD in cardiology and neurology market is segmented into immunoassays, molecular diagnostics, hematology, and other technologies. The immunoassays segment held a substantial revenue of USD 6.6 billion in 2023.
Based on end-use, the IVD in cardiology and neurology market is segmented into hospitals & clinics, diagnostic laboratories, and other end-users. The hospitals & clinics segment is anticipated to reach USD 12.9 billion by 2032.
In 2023, North America held a significant market share of 40.8% in the IVD in cardiology and neurology market and is predicted to witness substantial market growth over the analysis timeline.
Abbott Laboratories, Becton, Dickinson, and Company, bioMerieux S.A., Bio-Rad Laboratories, Inc., Danaher Corporation, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc.
North America held 40.8% of the IVD in cardiology and neurology industry share in 2023, and will witness significant growth till 2032, due to presence of well-established healthcare infrastructure, advanced diagnostic technologies, and a strong emphasis on R&D in the field of medicine.
The reagents, kits, & consumables product type segment is estimated to record USD 12 billion by the end of 2032, owing to higher adoption in diagnostic testing for cardiovascular and neurological disorders.
IVD in cardiology and neurology industry size was USD 15.6 billion in 2023 and is estimated to exceed USD 24 billion by 2032, due to increasing incidence and prevalence of cardiovascular diseases (CVDs) and neurological disorders like Alzheimer's disease, Parkinson's disease, and stroke.